← Blog

Endometrial Cancer: Prognosis, Survival Rates, and Key Prognostic Factors in Clinical Practice

Middle-aged Hispanic female doctor in her medical office reviewing data on endometrial cancer prognosis and survival rates on her computer. She is wearing a white coat and a stethoscope, with a poster of the female reproductive system in the background. The scene conveys professionalism and dedication to gynecological oncology, focusing on prognostic factors for endometrial cancer and uterine cancer life expectancy.

The endometrial cancer is the most common gynecological neoplasm in developed countries, and its incidence continues to rise. Despite advancements in diagnosis and treatment, the mortality associated with this type of cancer has also increased, underscoring the importance of understanding the factors that influence its prognosis and survival rates. In this context, it is crucial for healthcare professionals to stay informed about the latest research and developments in the management of this disease.

The prognosis of endometrial cancer is influenced by multiple factors, including histological type, tumor grade, and the presence of lymphovascular invasion. Type 1 tumors, which are hormone-sensitive and low-grade, generally have a favorable prognosis, while type 2 tumors are high-grade and tend to recur even at early stages [1]. Additionally, molecular classification has emerged as a valuable tool for improving risk stratification and treatment planning [2]. For instance, the mutation of the POLE gene is associated with a more favorable prognosis in high-grade endometrioid carcinomas [3].

Regarding survival rates, studies have shown that surgery remains the cornerstone of treatment, allowing for adequate staging and the possibility of personalized adjuvant treatments for high-risk patients [1]. The combination of chemotherapy and radiotherapy has not shown a significant improvement in relapse-free survival compared to chemotherapy alone in patients with advanced endometrial cancer [4]. However, the identification of biomarkers such as L1CAM and miR-34a may help identify subgroups of patients at higher risk of recurrence, suggesting the need for more aggressive treatments [5].

In conclusion, the management of endometrial cancer requires a multidisciplinary approach that considers both clinical and molecular factors to optimize prognosis and survival rates for patients. The integration of new technologies and the personalization of treatment are essential for improving outcomes in this complex disease. Ongoing research and medical education are fundamental to keeping us updated with advancements in this field.

Referencias


Created 13/1/2025